Trial Profile

A Phase I Clinical Trial for Evaluating the Safety, Tolerance and Efficacy of GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 13 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GPC3-targeting LCAR-H93T cell therapy-Affiliated Hospital of the Chinese Academy of Military Medical Sciences (Primary)
Indications Liver cancer
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

09 Aug 2024 Status changed from recruiting to discontinued (achieve the proof of concept).
11 Jun 2022 Status changed from not yet recruiting to recruiting.
09 May 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com